StockData
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY) stock

UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$3.35−0.18 (-5.10%)

Close on Nov 20, 2026Market cap $93.32MP/E –Yield –

Unicycive Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Unicycive Therapeutics's revenue for the twelve months ending Dec 31, 2023 was $675.00K, down 29.0% year over year. For fiscal 2023 it was $675.00K, down 29.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023$675.00K-29.0%
FY2022Dec 31, 2022$951.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$675.00K–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$951.00K–

More Unicycive Therapeutics figures

See a number that looks wrong?